Biogen expected to slightly beat Q3 earnings with lupus trial data due in Q4, says Jefferies

Biogen is forecasted to report a slight earnings per share beat for Q3 at $2.14 versus a consensus of $2.07, with revenue steady at $2.6 billion. The company may raise its 2026 revenue guidance amid cost shifts. Crucially, Biogen will release Phase III trial data for its lupus drug litifilimab in Q4, with Jefferies estimating a 60-65% chance of competitive efficacy. Positive trial results could boost Biogen's share price by 5-15% and support regulatory filings, while approval of a new Alzheimer's drug dosing method may accelerate sales in 2027.

As of Oct 07, 2026 01:41 WIB, Biogen Inc (BIIB) shares trade at USD 223.72 on Pluang, showing a slight increase of 0.06% over the past day. Despite the positive outlook on Q3 earnings and upcoming lupus trial data, Pluang order activity currently leans fully toward selling at 100%. The company's market capitalization stands at $33.04 billion, highlighting its significant presence in the health sector.